Pharmaceutical

XNK partners with Swedish hospital to develop AML therapy

XNK Therapeutics adds another research partner to evaluate XNK’s natural killer cell therapy candidate in acute myeloid leukaemia.

Aug 24, 2023 - 20:00
XNK partners with Swedish hospital to develop AML therapy
XNK Therapeutics adds another research partner to evaluate XNK’s natural killer cell therapy candidate in acute myeloid leukaemia.
Read the original article

Tags:

Previous Article

UK life sciences grapple with the job market’s digital dilemma

Next Article

FORE Biotherapeutics raises funding to expedite plixorafenib development

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

What’s next in the Kaiser Permanente strike

What’s next in the Kaiser Permanente strike

Oct 10, 2023

FDA grants ODD to Abdera’s neuroendocrine carcinoma treatment

FDA grants ODD to Abdera’s neuroendocrine carcinoma tre...

Sep 8, 2024

Watch: Why do we get seasonal allergies?

Watch: Why do we get seasonal allergies?

Jun 6, 2023